Novel therapeutic options in the inflammatory bowel disease world

Digestive and Liver Disease

Volumn 40, Issue 1, 2008, Pages 22-31

  Noble, A ^a   Baldassano, R ^a   Mamula, P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biologics; Children; Crohn's disease; Helminthes; Inflammatory bowel disease; Leukocyte apheresis; Probiotics; Stem cell transplantation; Ulcerative colitis

Indexed keywords

ABT 874; ADALIMUMAB; ALICAFORSEN; ANTIHISTAMINIC AGENT; ATLIZUMAB; BASILIXIMAB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; DRUG ANTIBODY; ETANERCEPT; FONTOLIZUMAB; INFLIXIMAB; MESALAZINE; METHOTREXATE; MLN 02; NATALIZUMAB; ONERCEPT; PLACEBO; PREDNISONE; PROBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; TETOMILAST; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL PAIN; ANOREXIA; APOPTOSIS; ASTHENIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACKACHE; BACTERIAL INFECTION; BONE PAIN; CHICKENPOX; CHILL; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COCCIDIOIDOMYCOSIS; CONGESTIVE HEART FAILURE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DEMYELINATING DISEASE; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ESOPHAGUS CANDIDIASIS; FLU LIKE SYNDROME; GRAFT REJECTION; HELMINTH; HEPATITIS; HERPES ZOSTER; HUMAN; INFECTION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; JC VIRUS; LETHARGY; LEUKAPHERESIS; LOADING DRUG DOSE; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOCYTOSIS; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MIGRAINE; MONOTHERAPY; NAUSEA AND VOMITING; NEUTROPHIL; NOCARDIOSIS; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PLEURA EFFUSION; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN TARGETING; PROTHROMBIN TIME; PYELONEPHRITIS; RECOMMENDED DRUG DOSE; REMISSION; ROTAVIRUS; SARCOIDOSIS; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE; THROMBOCYTOPENIA; THRUSH; TREATMENT DURATION; TUBERCULOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VIRUS INFECTION; VIRUS PNEUMONIA; VOMITING; WEAKNESS;

ANTI-INFLAMMATORY AGENTS; CELL MIGRATION INHIBITION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PROBIOTICS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37049033316     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.07.169     Document Type: Short Survey

References (81)

1. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
2. Sandborn W.J., Hanauer S.B., Rutgeerts P.J., Fedorak R.N., Lukas M., Macintosh D.G., et al. Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial. Gut 56 (2007) 1232-1239
3. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
4. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
5. Mian S., and Baron H. Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 41 (2005) 357-359
6. Deslandres C., Faure C., Dirks M., Gervais F., Seidman E., and Seidman E.G. Open label experience with adalimumab in pediatric Crohn's disease patients who lost response or were intolerant to infliximab. Gastroenterology 130, S2 (2006) A-656
7. Peyrin-Biroulet L., Laclotte C., Roblin X., and Bigard M.A. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study. World J Gastroenterol 13 (2007) 2328-2332
8. Colombel J.F., Sandborn W.J., Reinisch W., Hanauer S.B., Rutgeerts P.J., Sands B.E., et al. Adalimumab safety in Crohn's disease clinical trials. Gastroenterology 132 (2007, S2) A-504
9. Stack W.A., Mann S.D., Roy A.J., Heath P., Sopwith M., Freeman J., et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349 (1997) 521-524
10. Sandborn W.J., Feagan B.G., Hanauer S.B., Present D.H., Sutherland L.R., Kamm M.A., et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 120 (2001) 1330-1338
11. Sandborn W.J., Feagan B.G., Radford-Smith G., Kovacs A., Enns R., Innes A., et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53 (2004) 1485-1493
12. Feagan B.G., Sandborn W.J., Baker J.P., Cominelli F., Sutherland L.R., Elson C.O., et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 21 (2005) 373-384
13. Feagan B.G., Sandborn W.J., Lichtenstein G., Radford-Smith G., Patel J., Innes A., et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment Pharmacol Ther 23 (2006) 617-628
14. Winter T.A., Wright J., Ghosh S., Jahnsen J., Innes A., Round P., et al. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment Pharmacol & Ther 20 (2004) 1337-1346
15. Schreiber S., Rutgeerts P., Fedorak R.N., Khaliq-Kareemi M., Kamm M.A., Boivin M., et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129 (2005) 807-818
16. Sandborn W.J.F., Feagan B.G., Stoinov S., Honiball P.J., Rutgeerts P., McColm J.A., et al. Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Pase III study (PRECiSE 1). Gastroenterology 130 (2006, S2) A-9
17. Schreiber SF, Hanauer SB, Lichtenstein GR, Sandborn WJ. Superior efficacy of certolizumab pegol in early Crohn's disease is independent of CRP status. AGA abstract 2007.
18. Colombel JF, Schreiber SF, Hanauer SB, Rutgeerts P, Sandborn WJ. Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: results from PRECiSE 3 and 4. AGA abstract 2007.
19. Mamula P., Cohen S.A., Ferry G.D., Kirschner B.S., Winter H.S., Innes A., et al. CDP571, a humanized anti-tumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 10 (2004) 723-730
20. Evans R.C., Clarke L., Heath P., Stephens S., Morris A.I., Rhodes J.M., et al. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment Pharmacol Ther 11 (1997) 1031-1035
21. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
22. Rutgeerts P., Sandborn W.J., Fedorak R.N., Fedorak R.N., Rachmilewitz D., Tarabar D., et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 4 (2006) 888-893
23. Gordon F.H., Lai C.W., Hamilton M.I., Allison M.C., Srivastava E.D., Fouweather M.G., et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121 (2001) 268-274
24. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., et al. Natalizumab for active Crohn's disease. N Engl J Med 348 (2003) 24-32
25. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 353 (2005) 1912-1925
26. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 132 (2007) 1672-1683
27. Sands B.E., Kozarek R., Spainhour J., Barish C.F., Becker S., Goldberg L., et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 13 (2007) 2-11
28. Hyams J.S., Wilson D.C., Thomas A., Heuschkel R., Mitton S., Mitchell B., et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 44 (2007) 185-191
29. Gordon F.H., Hamilton M.I., Donoghue S., Greenlees C., Palmer T., Rowley-Jones D., et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 16 (2002) 699-705
30. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 354 (2006) 924-933
31. Feagan B., Greenberg G.R., Wild G., McDonald J.W., Fedorak R., Pare P., et al. Efficacy and safety of a humanized a4B7 antibody in active Crohn disease (CD). Gastroenterology 125 (2003) 605-607
32. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Paré P., McDonald J.W., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005) 2499-2507
33. Yacyshyn B.R., Bowen-Yacyshyn M.B., Jewell L., Tami J.A., Bennett C.F., Kisner D.L., et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114 (1998) 1133-1142
34. Yacyshyn B.R., Chey W.Y., Goff J., Salzberg B., Baerg R., Buchman A.L., et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 51 (2002) 30-36
35. Yacyshyn B., Chey W.Y., Wedel M.K., Yu R.Z., Paul D., Chuang E., et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 5 (2007) 215-220
36. Schreiber S., Nikolaus S., Malchow H., Kruis W., Lochs H., Raedler A., et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 120 (2001) 1339-1346
37. Van Deventer S.J., Tami J.A., and Wedel M.K. A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut 53 (2004) 1646-1651
38. Van Deventer S.J., Wedel M.K., Baker B.F., Xia S., Chuang E., Miner P.B., et al. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 23 (2006) 1415-1425
39. Miner P.B., Wedel M.K., Xia S., and Baker B.F. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther 23 (2006) 1403-1413
40. Van Assche G., Dalle I., Noman M., Aerden I., Swijsen C., Asnong K., et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol 98 (2003) 369-376
41. Van Assche G., Sandborn W.J., Feagan B.G., Salzberg B.A., Silvers D., Monroe P.S., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55 (2006) 1568-1574
42. Creed T.J., Norman M.R., Probert C.S., Harvey R.F., Shaw I.S., Smithson J., et al. Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther 18 (2003) 65-75
43. Creed T.J., Probert C.S., Norman M.N., Moorghen M., Shepherd N.A., Hearing S.D., et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 23 (2006) 1435-1442
44. Mannon P.J., Fuss I.J., Mayer L., Elson C.O., Sandborn W.J., Present D., et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 351 (2004) 2069-2079
45. Hommes D.W., Mikhajlova T.L., Stoinov S., Stimac D., Vucelic B., Lonovics J., et al. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55 (2006) 1131-1137
46. Reinisch W., Hommes D.W., Van Assche G., Colombel J.F., Gendre J.P., Oldenburg B., et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 55 (2006) 1138-1144
47. Fedorak R.N., Gangl A., Elson C.O., Rutgeerts P., Schreiber S., Wild G., et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119 (2000) 1473-1482
48. Van Deventer S.J., Elson C.O., and Fedorak R.N. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 113 (1997) 383-389
49. Schreiber S., Fedorak R.N., Nielsen O.H., Wild G., Williams C.N., Nikolaus S., et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 119 (2000) 1461-1472
50. Colombel J.F., Rutgeerts P., Malchow H., Jacyna M., Nielsen O.H., Rask-Madsen J., et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49 (2001) 42-46
51. Ito H., Takazoe M., Fukuda Y., Hibi T., Kusugami K., Andoh A., et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126 (2004) 989-996
52. Plevy S.E., Salzberg B.A., Regueiro M., Sandborn W., Hanauer S.B., Targan S.R., et al. A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: results of a phase I study. Gastroenterology 124, S1 (2003) A7
53. Targan S.R., Salzberg B.A., Mayer L., Hommes D., Hanauer S., Mahadevan U., et al. A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with IV steroids (IVSR-UC). Gastroenterology 128, S2 (2005) A-75
54. Travis S., Yap L.M., Hawkey C., Warren B., Lazarov M., Fong T., et al. RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm Bowel Dis 11 (2005) 713-719
55. Schreiber S., Keshavarzian A., Isaacs K.L., Schollenberger J., Guzman J.P., Orlandi C., et al. A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis. Gastroenterology 132 (2007) 76-86
56. Winkelstein J.A., Marino M.C., Johnston R.B., Boyle J., Curnutte J., Gallin J.I., et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 79 (2000) 155-169
57. Melis D., Parenti G., Della Casa R., Sibilio M., Berni Canani R., Terrin G., et al. Crohn's-like ileo-colitis in patients affected by glycogen storage disease Ib: two years' follow-up of patients with a wide spectrum of gastrointestinal signs. Acta Paediatr 92 (2003) 1415-1421
58. Myrup B., Valerius N.H., and Mortensen P.B. Treatment of enteritis in chronic granulomatous disease with granulocyte colony stimulating factor. Gut 42 (1998) 127-130
59. Roe T.F., Coates T.D., Thomas D.W., Miller J.H., and Gilsanz V. Brief report: treatment of chronic inflammatory bowel disease in glycogen storage disease type Ib with colony-stimulating factors. N Engl J Med 326 (1992) 1666-1669
60. Wang J., Mayer L., and Cunningham-Rundles C. Use of GM-CSF in the treatment of colitis associated with chronic granulomatous disease. J Allergy Clin Immunol 115 (2005) 1092-1094
61. Korzenik J.R., and Dieckgraefe B.K. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 21 (2005) 391-400
62. Dieckgraefe B.K., and Korzenik J.R. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360 (2002) 1478-1480
63. Korzenik J.R., Dieckgraefe B.K., Valentine J.F., Hausman D.F., and Gilbert M.J. Sargramostim for active Crohn's disease. N Engl J Med 352 (2005) 2193-2201
64. Leung Y., Geddes M., Storek J., Panaccione R., and Beck P.L. Hematopoietic cell transplantation for Crohn's disease; is it time?. World J Gastroenterol 12 (2006) 6665-6673
65. Oyama Y., Craig R.M., Traynor A.E., Quigley K., Statkute L., Halverson A., et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 128 (2005) 552-563
66. Burt R.K., Traynor A., Oyama Y., and Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101 (2003) 2064-2066
67. Kohgo Y., Ashida T., Maemoto A., and Ayabe T. Leukocytapheresis for treatment of IBD. J Gastroenterol 38, S15 (2003) 51-4
68. Sawada K., Muto T., Shimoyama T., Satomi M., Sawada T., Nagawa H., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 (2003) 307-321
69. Sawada K., Kusugami K., Suzuki Y., Bamba T., Munakata A., Hibi T., et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 100 (2005) 1362-1369
70. Hanai H., Watanabe F., Yamada M., Sato Y., Takeuchi K., Iida T., et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 70 (2004) 36-44
71. Lerebours E., Bussel A., Modigliani R., Bastit D., Florent C., Rabian C., et al. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 107 (1994) 357-361
72. Weinstock J.V. Helminths and mucosal immune modulation. Ann N Y Acad Sci 1072 (2006) 356-364
73. Summers R.W., Elliott D.E., Qadir K., Urban J.F., Thompson R., Weinstock J.V., et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol 98 (2003) 2034-2041
74. Summers R.W., Elliott D.E., Urban J.F., Thompson R., and Weinstock J.V. Trichuris suis therapy in Crohn's disease. Gut 54 (2005) 87-90
75. Summers R.W., Elliott D.E., Urban J.F., Thompson R.A., and Weinstock J.V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005) 825-832
76. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
77. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
78. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53 (2004) 108-114
79. Kruis W., Fric P., Pokrotnieks J., Lukás M., Fixa B., Kascák M., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
80. Bousvaros A., Guandalini S., Baldassano R.N., Botelho C., Evans J., Ferry G.D., et al. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11 (2005) 833-839
81. Marteau P., Lemann M., Seksik P., Laharie D., Colombel J.F., Bouhnik Y., et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55 (2006) 842-847